Ga-68-Prostate-specific membrane antigen (PSMA) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis

Imagem de Miniatura
Arquivos
art_MATUSHITA_Ga68Prostatespecific_membrane_antigen_PSMA_positron_emission_tomography_pet_2021.PDF (7.21 MB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2021
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BRAZILIAN SOC UROL
Autores
MATUSHITA, Cristina S.
SILVA, Ana M. Marques da
SCHUCK, Phelipi N.
BARDISSEROTTO, Matteo
PIANT, Diego B.
PEREIRA, Jonatas L.
CERCI, Juliano J.
ESTEVES, Fabio P.
AMORIM, Barbara J.
Citação
INTERNATIONAL BRAZ J UROL, v.47, n.4, p.705-729, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Prostate cancer (PC) is the second most commonly diagnosed cancer in males. Ga-68-PSMA PET/CT, a non-invasive diagnostic tool to evaluate PC with prostate-specific membrane antigen (PSMA) expression, has emerged as a more accurate alternative to assess disease staging. We aimed to identify predictors of positive Ga-68-PSMA PET and the accuracy of this technique. Materials and methods: Diagnostic accuracy cross-sectional study with prospective and retrospective approaches. We performed a comprehensive literature search on PubMed, Cochrane Library, and Embase database in search of studies including PC patients submitted to radical prostatectomy or radiotherapy with curative intent and presented biochemical recurrence following ASTRO 1996 criteria. A total of 35 studies involving 3910 patients submitted to 68-Ga-PSMA PET were included and independently assessed by two authors: 8 studies on diagnosis, four on staging, and 23 studies on restaging purposes. The significance level was alpha=0.05. Results: pooled sensitivity and specificity were 0.90 (0.86-0.93) and 0.90 (0.82-0.96), respectively, for diagnostic purposes; as for staging, pooled sensitivity and specificity were 0.93 (0.86-0.98) and 0.96 (0.92-0.99), respectively. In the restaging scenario, pooled sensitivity and specificity were 0.76 (0.74-0.78) and 0.45 (0.27-0.58), respectively, considering the identification of prostate cancer in each described situation. We also obtained specificity and sensitivity results for PSA subdivisions. Conclusion: Ga-68-PSMA PET provides higher sensitivity and specificity than traditional imaging for prostate cancer.
Palavras-chave
Prostate cancer, familial [Supplementary Concept], Glu-NH-CO-NH-Lys-(Ahx)-((68) Ga(HBED-CC)) [Supplementary Concept], (225)Ac-PSMA-617 [Supplementary Concept]
URI
https://observatorio.fm.usp.br/handle/OPI/44644
Referências
  1. Afaq A, 2018, J NUCL MED, V59, P89, DOI 10.2967/jnumed.117.192625
  2. Afshar-Oromieh A, 2013, EUR J NUCL MED MOL I, V40, P971, DOI 10.1007/s00259-013-2386-y
  3. Afshar-Oromieh A, 2017, J NUCL MED, V58, P750, DOI 10.2967/jnumed.116.183483
  4. Afshar-Oromieh A, 2015, J NUCL MED, V56, P1697, DOI 10.2967/jnumed.115.161299
  5. Afshar-Oromieh A, 2015, EUR J NUCL MED MOL I, V42, P197, DOI 10.1007/s00259-014-2949-6
  6. Afshar-Oromieh A, 2014, EUR J NUCL MED MOL I, V41, P11, DOI 10.1007/s00259-013-2525-5
  7. Akdemir EN, 2019, WORLD J UROL, V37, P813, DOI 10.1007/s00345-018-2460-y
  8. Barbaud M, 2019, PROSTATE, V79, DOI 10.1002/pros.23751
  9. Bashir U, 2019, EUR J NUCL MED MOL I, V46, P901, DOI 10.1007/s00259-018-4249-z
  10. Berliner C, 2017, EUR J NUCL MED MOL I, V44, P670, DOI 10.1007/s00259-016-3572-5
  11. Bluemel C, 2016, CLIN NUCL MED, V41, P515, DOI 10.1097/RLU.0000000000001197
  12. Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31
  13. Zang SM, 2017, ONCOTARGET, V8, P12247, DOI 10.18632/oncotarget.14691
  14. Zhang JL, 2019, EUR J NUCL MED MOL I, V46, P908, DOI 10.1007/s00259-018-4255-1
  15. ANN NUCL MED
  16. Brauer A, 2017, NUKLEARMED-NUCL MED, V56, P14, DOI 10.3413/Nukmed-0846-16-09
  17. Budaus L, 2016, EUR UROL, V69, P393, DOI 10.1016/j.eururo.2015.06.010
  18. Calais J, 2018, J NUCL MED, V59, P434, DOI 10.2967/jnumed.117.202945
  19. Calais J, 2018, J NUCL MED, V59, P230, DOI 10.2967/jnumed.117.201749
  20. Caroli P, 2018, EUR J NUCL MED MOL I, V45, P2035, DOI 10.1007/s00259-018-4067-3
  21. Ceci F, 2019, EUR J NUCL MED MOL I, V46, P31, DOI 10.1007/s00259-018-4189-7
  22. Ceci F, 2015, EUR J NUCL MED MOL I, V42, P1284, DOI 10.1007/s00259-015-3078-6
  23. Demirkol MO, 2015, PROSTATE, V75, P748, DOI 10.1002/pros.22956
  24. DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
  25. Dewes S, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0646-2
  26. Dietlein F, 2017, J NUCL MED, V58, P947, DOI 10.2967/jnumed.116.185538
  27. Dietlein M, 2015, MOL IMAGING BIOL, V17, P575, DOI 10.1007/s11307-015-0866-0
  28. Dyrberg E, 2019, EUR RADIOL, V29, P1221, DOI 10.1007/s00330-018-5682-x
  29. Eder M, 2012, BIOCONJUGATE CHEM, V23, P688, DOI 10.1021/bc200279b
  30. Eiber M, 2016, EUR UROL, V70, P829, DOI 10.1016/j.eururo.2015.12.053
  31. Eiber M, 2015, J NUCL MED, V56, P668, DOI 10.2967/jnumed.115.154153
  32. Einspieler I, 2017, J NUCL MED, V58, P1081, DOI 10.2967/jnumed.116.184457
  33. Ergul N, 2018, CLIN NUCL MED, V43, pE422, DOI 10.1097/RLU.0000000000002289
  34. Fendler WP, 2019, JAMA ONCOL, V5, P856, DOI 10.1001/jamaoncol.2019.0096
  35. Fendler WP, 2016, J NUCL MED, V57, P1720, DOI 10.2967/jnumed.116.172627
  36. Fendler WP, 2017, J NUCL MED, V58, P1617, DOI 10.2967/jnumed.117.190827
  37. Fennessy N, 2017, J MED IMAG RADIAT ON, V61, P739, DOI 10.1111/1754-9485.12625
  38. Gauthe M, 2017, PROG UROL, V27, P474, DOI 10.1016/j.purol.2017.04.004
  39. Giesel FL, 2016, EUR J NUCL MED MOL I, V43, P1400, DOI 10.1007/s00259-016-3346-0
  40. Grubmuller B, 2018, EUR J NUCL MED MOL I, V45, P235, DOI 10.1007/s00259-017-3858-2
  41. Gupta Manoj, 2017, World J Nucl Med, V16, P186, DOI 10.4103/1450-1147.207272
  42. Hamed MAG, 2019, ACAD RADIOL, V26, P450, DOI 10.1016/j.acra.2018.05.020
  43. HECK M, 2016, EUR J NUCL MED MOL I, V43, P2114
  44. Henkenberens C, 2016, STRAHLENTHER ONKOL, V192, P431, DOI 10.1007/s00066-016-0982-z
  45. Herlemann A, 2016, EUR UROL, V70, P553, DOI 10.1016/j.eururo.2015.12.051
  46. Herrmann K, 2015, J NUCL MED, V56, P855, DOI 10.2967/jnumed.115.156133
  47. Hicks RM, 2018, RADIOLOGY, V289, P730, DOI 10.1148/radiol.2018180788
  48. Higgins JPT, 2020, COCHRANE HDB SYSTEMA, DOI 10.1002/9780470712184
  49. Hijazi S, 2015, PROSTATE, V75, P1934, DOI 10.1002/pros.23091
  50. Hope TA, 2017, J NUCL MED, V58, P1956, DOI 10.2967/jnumed.117.192476
  51. Hruby G, 2018, ASIA-PAC J CLIN ONCO, V14, P343, DOI 10.1111/ajco.12872
  52. Hruby G, 2017, RADIOTHER ONCOL, V122, P99, DOI 10.1016/j.radonc.2016.11.023
  53. HSU IC, 2019, UROLOGY, V125, P154
  54. Jilg CA, 2017, THERANOSTICS, V7, P1770, DOI 10.7150/thno.18421
  55. Kabasakal L, 2017, NUCL MED COMMUN, V38, P149, DOI 10.1097/MNM.0000000000000617
  56. Kabasakal L, 2015, NUCL MED COMMUN, V36, P582, DOI 10.1097/MNM.0000000000000290
  57. Kuten J, 2019, ISR MED ASSOC J, V21, P100
  58. Lengana T, 2018, CLIN GENITOURIN CANC, V16, P392, DOI 10.1016/j.clgc.2018.07.009
  59. Liberati A., 2009, BMJ, V62, pe1, DOI [10.1016/j.jclinepi.2009.06.006, DOI 10.1136/BMJ.B2700]
  60. Lopci E, 2018, J UROLOGY, V200, P95, DOI 10.1016/j.juro.2018.01.079
  61. LOTZ J, 2016, EUR J NUCL MED MOL I, V43, P898
  62. Mattiolli AB, 2018, INT BRAZ J UROL, V44, P892, DOI [10.1590/S1677-5538.IBJU.2017.0632, 10.1590/s1677-5538.ibju.2017.0632]
  63. Maurer T, 2016, J UROLOGY, V195, P1436, DOI 10.1016/j.juro.2015.12.025
  64. McCarthy M, 2019, INT J RADIAT ONCOL, V104, P801, DOI 10.1016/j.ijrobp.2019.03.014
  65. Meredith G, 2016, BJU INT, V118, P49, DOI 10.1111/bju.13616
  66. Morigi JJ, 2015, J NUCL MED, V56, P1185, DOI 10.2967/jnumed.115.160382
  67. National Cancer Institute Surveillance Epidemiology and End Results Program, CANC STAT FACTS PROS
  68. Perera M, 2016, EUR UROL, V70, P926, DOI 10.1016/j.eururo.2016.06.021
  69. Pfister D, 2016, EUR J NUCL MED MOL I, V43, P1410, DOI 10.1007/s00259-016-3366-9
  70. Rahbar K, 2016, J NUCL MED, V57, P563, DOI 10.2967/jnumed.115.169243
  71. Rauscher I, 2016, J NUCL MED, V57, P1713, DOI 10.2967/jnumed.116.173492
  72. Rhee H, 2016, J UROLOGY, V196, P1261, DOI 10.1016/j.juro.2016.02.3000
  73. Roach M, 2006, INT J RADIAT ONCOL, V65, P965, DOI 10.1016/j.ijrobp.2006.04.029
  74. Roach PJ, 2018, J NUCL MED, V59, P82, DOI 10.2967/jnumed.117.197160
  75. Sachpekidis C, 2016, EUR J NUCL MED MOL I, V43, P1288, DOI 10.1007/s00259-015-3302-4
  76. Sachpekidis C, 2016, CLIN NUCL MED, V41, pE473, DOI 10.1097/RLU.0000000000001349
  77. Schmidkonz C, 2018, CLIN NUCL MED, V43, P225, DOI 10.1097/RLU.0000000000001991
  78. Schmidt-Hegemann NS, 2019, J NUCL MED, V60, P963, DOI 10.2967/jnumed.118.220855
  79. Schmuck S, 2017, EUR J NUCL MED MOL I, V44, P960, DOI 10.1007/s00259-017-3669-5
  80. Schwenck J, 2017, EUR J NUCL MED MOL I, V44, P92, DOI 10.1007/s00259-016-3490-6
  81. Soldatov A, 2019, INT J RADIAT ONCOL, V103, P95, DOI 10.1016/j.ijrobp.2018.08.066
  82. Steele CB, 2017, CANCER-AM CANCER SOC, V123, P5160, DOI 10.1002/cncr.31026
  83. Thomas L, 2018, EUR J NUCL MED MOL I, V45, P1170, DOI 10.1007/s00259-018-3954-y
  84. Umbehr MH, 2013, EUR UROL, V64, P106, DOI 10.1016/j.eururo.2013.04.019
  85. Uprimny C, 2018, EUR J NUCL MED MOL I, V45, P1873, DOI 10.1007/s00259-018-4048-6
  86. Uprimny C, 2017, EUR J NUCL MED MOL I, V44, P1647, DOI 10.1007/s00259-017-3743-z
  87. Uprimny C, 2017, EUR J NUCL MED MOL I, V44, P941, DOI 10.1007/s00259-017-3631-6
  88. Uprimny C, 2017, EUR J NUCL MED MOL I, V44, P765, DOI 10.1007/s00259-016-3578-z
  89. Uslu-Besli L, 2019, TURK J MED SCI, V49, P301, DOI 10.3906/sag-1807-4
  90. van Leeuwen PJ, 2017, BJU INT, V119, P209, DOI 10.1111/bju.13540
  91. van Leeuwen PJ, 2016, BJU INT, V117, P732, DOI 10.1111/bju.13397
  92. Verburg FA, 2016, EUR J NUCL MED MOL I, V43, P397, DOI 10.1007/s00259-015-3240-1
  93. Vinsensia M, 2017, J NUCL MED, V58, P1949, DOI 10.2967/jnumed.116.185033
  94. von Klot CAJ, 2017, NUCL MED MOLEC IMAG, V51, P314, DOI 10.1007/s13139-017-0476-7
  95. Walacides D, 2019, STRAHLENTHER ONKOL, V195, P420, DOI 10.1007/s00066-018-1417-9
  96. Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
  97. Wondergem M, 2017, J NUCL MED, V58, P1797, DOI 10.2967/jnumed.117.192658
  98. Wong HS, 2018, J MED IMAG RADIAT ON, V62, P816, DOI 10.1111/1754-9485.12791
  99. Zacho HD, 2018, EUR J NUCL MED MOL I, V45, P1884, DOI 10.1007/s00259-018-4058-4
  100. Zamboglou C, 2017, THERANOSTICS, V7, P228, DOI 10.7150/thno.16638
  101. Zamboglou C, 2016, THERANOSTICS, V6, P1619, DOI 10.7150/thno.15344

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/43
Artigos e Materiais de Revistas Científicas - LIM/47
Artigos e Materiais de Revistas Científicas - ODS/03